Latest News
-

The road ahead for uniQure: FDA says more data needed for AMT-130 gene therapy
⏱️ 10 min read | The FDA wants more data before approving AMT-130 for Huntington’s disease in the U.S. On March 2026, uniQure shared in an update that current Phase 1/2 data weren’t enough for the agency. A new randomized, sham-controlled trial may be required.
-

What the 'big neurodegeneration breakthrough' means for Huntington's disease
Are recent findings in mice injected with 'prions' as important for Huntington's disease as widely reported?
-

Buzzilia Video: Day 1
Buzzilia video: Day 1. Highlights of the 2013 HD World Congress in Brazil: nightly news, interviews and features
-

Video feature: Huntington's disease research… in space!
The sky's no longer the limit for HD research: HDBuzz interviews Gwen Owens, who's sending the HD protein into space!
-

'Buzzilia' from the Huntington's Disease World Congress: day 4
#Buzzilia, day 4: Jeff and Ed's roundup of happenings from the closing day of the HD World Congress in Rio de Janeiro
-

'Buzzilia' from the Huntington's Disease World Congress: day 3
#Buzzilia, day 3: Jeff and Ed's roundup of happenings from the third day of the HD World Congress in Rio de Janeiro
-

'Buzzilia' from the Huntington's Disease World Congress: day 2
#Buzzilia, day 2: Jeff and Ed's roundup of happenings from the second day of the HD World Congress in Rio de Janeiro
-

'Buzzilia' from the Huntington's Disease World Congress: day 1
#Buzzilia, day 1: Jeff and Ed's roundup of happenings from the opening day of the HD World Congress in Rio de Janeiro
-

Coming soon from the 2013 Huntington's Disease World Congress: Buzzilia!
HDBuzz presents 'Buzzilia!', our reports from the 2013 HD World Congress in Rio de Janeiro, from Sun 15 September
-

Could muscle problems help explain movements in Huntington’s Disease patients?
Proper contraction of muscles is crucial for coordination; errors in this process might help explain movements in HD

